GlaxoSmithKline (GSK) has announced promising data for its Zejula (niraparib) drug as a...
- GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
- Broader inclusion criteria to double eligible cancer patients for clinical trials, finds study
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
- Industry Viewpoints: Choosing the Right CRO
- Expert Insights: Moderna Therapeutics Barrels Ahead Towards Historic IPO
Xpovio (selinexor) for the Treatment of Multiple Myeloma
Xpovio™ (selinexor) is the first nuclear export inhibitor approved in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma (RRMM) in adult patients.
Lynparza improves survival in Phase III ovarian cancer patients
AstraZeneca and MSD have reported that the Phase III PAOLA-1 study of Lynparza (olaparib) in combination with bevacizumab met the primary endpoint in advanced ovarian cancer patients.
Deciphera reports positive results from INVICTUS study
Deciphera Pharmaceuticals has announced positive findings from the Phase III INVICTUS clinical trial that evaluated ripretinib for the treatment of fourth-line and fourth-line plus gastrointestinal stromal tumours (GIST).
Basilea initiates trial of derazantinib to treat urothelial cancer
Swiss biopharmaceutical firm Basilea Pharmaceutica has launched a clinical trial to assess derazantinib both as a monotherapy and with Roche's atezolizumab to treat urothelial cancer.
Onconova, Mission Bio partner to advance oncology trials using single-cell genomics
Onconova Therapeutics has formed a strategic collaboration to use Mission Bio’s Tapestri platform for targeted single-cell DNA analysis in order to study its novel cancer therapy, rigosertib, through clinical trials.
AstraZeneca reports positive results from trial of Tagrisso
AstraZeneca has reported positive results from the Phase III Flaura trial evaluating Tagrisso (osimertinib) in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC).
Coordination Pharmaceuticals doses first patient in CPI-200 trial
Coordination Pharmaceuticals (CPI) has dosed the first patient in a Phase I study of nanoscale coordination polymer (NCP) CPI-200 in patients with advanced tumours.
AstraZeneca and MSD report positive data from trial of Lynparza
AstraZeneca and MSD have reported positive results from the Phase III PROfound trial evaluating the safety and efficacy of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC).
Turalio (pexidartinib) for the Treatment of Tenosynovial Giant Cell Tumour
Turalio™ (pexidartinib) is the first drug approved for the treatment of tenosynovial giant cell tumour (TGCT) in adult patients.
Jazz Pharmaceuticals to initiate study of JZP-458 to treat ALL
Jazz Pharmaceuticals is set to initiate a single-arm, pivotal Phase II/III study of JZP-458 as a potential treatment option for acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LBL) patients.